From GlobeNewswire:

Oculis Holding AG, a biopharmaceutical company, had a successful year with a NASDAQ listing and positive results from Phase 3 trials for OCS-01 in Diabetic Macular Edema and post-cataract surgery inflammation. The company is set to report data from additional trials in 2024 with cash reserves of $108.9 million. The company’s innovative pipeline includes potential treatments for Dry Eye Disease and Acute Optic Neuritis. Oculis aims to advance its research and submit its first NDA this year. Financially, the company saw an increase in cash position compared to 2022, with R&D expenses increasing due to new clinical trials. Net loss for Q4 2023 and full year 2023 increased, primarily due to merger and listing expenses, higher clinical development expenses, and fair value adjustments. The company uses non-IFRS financial measures to analyze operating performance and financial outlook.



Read more at GlobeNewswire:: Oculis Reports Q4 and Full Year 2023 Financial Results and